Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.
paper
Cited
Public
- Authors
- Conti, David V; Lee, Won; Li, Dalin; Liu, Jinghua; Van Den Berg, David; Thomas, Paul D; Bergen, Andrew W; Swan, Gary E; Tyndale, Rachel F; Benowitz, Neal L; Lerman, Caryn; Pharmacogenetics of Nicotine Addiction and Treatment Consortium
- Year
- 2008
- Journal
- Human molecular genetics
- PMID
- 18593715
- DOI
- 10.1093/hmg/ddn181
- PMCID
- PMC2525499
Although the efficacy of pharmacotherapy for tobacco dependence has been previously demonstrated, there is substantial variability among individuals in treatment response. We performed a systems-based candidate gene study of 1295 single nucleotide polymorphisms (SNPs) in 58 genes within the neuronal nicotinic receptor and dopamine systems to investigate their role in smoking cessation in a bupropion placebo-controlled randomized clinical trial. Putative functional variants were supplemented with tagSNPs within each gene. We used global tests of main effects and treatment interactions, adjusting the P-values for multiple correlated tests. An SNP (rs2072661) in the 3' UTR region of the beta2 nicotinic acetylcholine receptor subunit (CHRNB2) has an impact on abstinence rates at the end of treatment (adjusted P = 0.01) and after a 6-month follow-up period (adjusted P = 0.0002). This latter P-value is also significant with adjustment for the number of genes tested. Independent of treatment at 6-month follow-up, individuals carrying the minor allele have substantially decreased the odds of quitting (OR = 0.31; 95% CI 0.18-0.55). Effect of estimates indicate that the treatment is more effective for individuals with the wild-type (OR = 2.14, 95% CI 1.20-3.81) compared with individuals carrying the minor allele (OR = 0.83, 95% CI 0.32-2.19), although this difference is only suggestive (P = 0.10). Furthermore, this SNP demonstrated a role in the time to relapse (P = 0.0002) and an impact on withdrawal symptoms at target quit date (TQD) (P = 0.0009). Overall, while our results indicate strong evidence for CHRNB2 in ability to quit smoking, these results require replication in an independent sample.
Block structure for CHRNB2 from HapMap Genome Build 36. The linkage disequilibrium (LD) plot was obtained using Haploview (25) and HapMap Build 36. The scale at the top of the figure depicts the HapMap region for CHRNB2 (Chromosome 1: 152,806,881 to 152,818,975), and roughly 10 kb upstream and downstream of this region. Single nucleotide polymorphisms (SNPs) genotyped by HapMap are identified in blue (minor alleles) and red (major alleles). Gene regions with the direction of their respective reading frame, exons, and introns, are also given. The 13 SNPs in boxes are the tagSNPs selected in this gene region. rs2072658 and rs2072661 have no HapMap or LD information. The r2 LD color scheme is depicted. Two blocks are delineated using the default block definitions from Haploview.
Figure 2.
Abstinence rates by CHRNB2 rs2072661 and by bupropion treatment. Abstinence rates comparing individuals with at least one variant allele for CHRNB2 rs2072661 (filled bars) to those with both common alleles (unfilled bars) were stratified by treatment (buproprion or placebo) and estimated at each time point (end of treatment and 6-month follow-up).
Figure 3.
Time to relapse to 6-month follow-up for CHRNB2 rs2072661. Time to relapse to 6-month follow-up in individuals with at least one variant allele for CHRNB2 rs2072661 (thin lines) was compared with those having both alleles common (thick lines), stratifying by treatment group: buproprion (dotted lines) and placebo (solid lines).
β Prev
41β53 of 53
| Name | Type |
|---|---|
| 6-month follow-up local | phenotype |
| 7-day point prevalence abstinence local | phenotype |
| abstinence | phenotype |
| abstinence at 6-month follow-up local | phenotype |
| abstinence at EOT | phenotype |
| ADCYAP1 local | gene |
| addiction | phenotype |
| African | cohort |
| African-Americans | cohort |
| age | phenotype |
| AIMs | variant |
| American Indian local | phenotype |
| Amerindian | cohort |
| ancestry informative markers | variant |
| ancestry informative SNPs local | variant |
| ANKK1 | gene |
| anxiousness | phenotype |
| Asian | cohort |
| Bdnf | gene |
| brain stimulation reward thresholds local | phenotype |
| bupropion | drug |
| bupropion trial local | cohort |
| candidate genes | cohort |
| Caucasian | cohort |
| Caucasian cohort | cohort |
| Caucasian-only sample local | cohort |
| Caucasians | cohort |
| Cdk5 | gene |
| CEPH | cohort |
| CEPH trios local | cohort |
| CEU | cohort |
| Chinese HapMap population local | cohort |
| Chinese population | cohort |
| Chrna3 | gene |
| Chrna4 | gene |
| CHRNA5 | gene |
| Chrna6 | gene |
| Chrnb2 | gene |
| Chrnb3 | gene |
| clinical trial | cohort |
| cognition | phenotype |
| conditioned nicotine reinforcement local | phenotype |
| cotinine | drug |
| days to relapse local | phenotype |
| dbSNP | cohort |
| difficulty in concentrating local | phenotype |
| dizziness | phenotype |
| dopamine | drug |
| dopamine biosynthesis enzymes local | gene |
| dopamine receptors local | gene |
| dopaminergic neurons | anatomy |
| Dopamine transporter | drug |
| DRD1 | gene |
| DRD2 | gene |
| DRD3 | gene |
| drowsiness | phenotype |
| DSM-IV axis I psychiatric disorder local | phenotype |
| East Asian | cohort |
| EOT local | phenotype |
| European ancestry | cohort |
| FagerstrΓΆm Test for Nicotine Dependence | phenotype |
| Fosb | gene |
| FTND | phenotype |
| gDNA local | drug |
| genomic DNA | drug |
| Georgetown University local | cohort |
| GoldenGateβ’ assay local | drug |
| haplotype 11001011 local | variant |
| haplotype 11101011 local | variant |
| HapMap | cohort |
| HapMap SNP data local | variant |
| Hispanic | phenotype |
| Htr1b | gene |
| Illumina assay local | drug |
| Illumina genotyping | drug |
| Illumina platform | drug |
| initial subjective response to nicotine local | phenotype |
| insomnia | phenotype |
| irritability | phenotype |
| minor allele | variant |
| Multiethnic Cohort Diversity Panel local | cohort |
| Multi-Ethnic Cohort Diversity Panel local | cohort |
| multi-ethnic sample local | cohort |
| multiple ethnic groups local | cohort |
| Native Hawaiians | cohort |
| nausea | phenotype |
| neuronal nicotinic acetylcholine receptors local | gene |
| nicotine | drug |
| nicotine addiction | phenotype |
| nicotine dependence | phenotype |
| nicotine-mediated dopamine release local | phenotype |
| nicotine self-administration | phenotype |
| nicotine withdrawal | phenotype |
| nicotine withdrawal syndrome local | phenotype |
| NTRK2 | gene |
| participants | cohort |
| Pharmacogenetics of Nicotine Addiction and Treatment Consortium local | cohort |
| phenotype | phenotype |
| placebo-controlled randomized clinical trial local | cohort |
| Placebo-Controlled Trial local | cohort |
| quitting | phenotype |
| relapse | phenotype |
| relapse risk | phenotype |
| risk allele | cohort |
| rs10517626 local | variant |
| rs1127314 | variant |
| rs2072658 | variant |
| rs2072660 | variant |
| rs2072661 | variant |
| rs2131902 local | variant |
| rs2236196 | variant |
| rs3766925 local | variant |
| rs3766927 | variant |
| rs9427092 local | variant |
| self-reported abstinence | phenotype |
| sex | phenotype |
| smokers who initiated local | cohort |
| smoking | phenotype |
| smoking abstinence | phenotype |
| smoking cessation | phenotype |
| Snagger software local | drug |
| SNP | cohort |
| SUNY Buffalo local | cohort |
| sweating | phenotype |
| tagSNP | variant |
| TaqMan assay | drug |
| target quit data (TQD) local | phenotype |
| TDO2 local | gene |
| time to first cigarette | phenotype |
| time to first relapse local | phenotype |
| time to relapse | phenotype |
| tobacco use | phenotype |
| top SNPs | cohort |
| treatment | phenotype |
| University of Pennsylvania Nicotine Replacement Trial local | cohort |
| University of Pennsylvania Transdisciplinary Tobacco Use Research Center local | cohort |
| USC Transdisciplinary Tobacco Use Research Center local | cohort |
| varenicline | drug |
| ventral striatum | anatomy |
| wgaDNA local | drug |
| whole genome-amplified DNA local | drug |
| wild-type mice | cohort |
| withdrawal | phenotype |
| withdrawal severity index local | phenotype |
| withdrawal symptoms at TQD local | phenotype |
| WT genotype local | variant |
| Ξ±4Ξ²2 nAChR | drug |
| Ξ²2 knockout mice local | cohort |
| Ξ²2 subunit-containing nAChRs local | drug |
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| CHRNA5-A3-B4, CYP2A6, and DBH Genetic Associations With Smoking Cessation Throughout Adulthood Within Two Longitudinal Studies of Women. | Jones SK et al. | β | 2025 | β |
| Neuroprotective and antimalarial effects of <i>Juglans regia</i> leaf extracts in a murine model of cerebral malaria. | Alharbi A et al. | β | 2025 | β |
| Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. | Cinciripini PM et al. | β | 2024 | β |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | β | 2023 | β |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | β | 2023 | β |
| CHRNA5-A3-B4 and DRD2 Genes and Smoking Cessation Throughout Adulthood: A Longitudinal Study of Women. | Jones SK et al. | β | 2023 | β |
| Genetic Associations with Smoking Relapse and Proportion of Follow-up in Smoking Relapse throughout Adulthood in Pre- and Postmenopausal Women. | Jones SK et al. | β | 2023 | β |
| A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. | Jones SK et al. | β | 2022 | β |
| Antidepressants for smoking cessation. | Howes S et al. | β | 2020 | β |
| Determining population stratification and subgroup effects in association studies of rare genetic variants for nicotine dependence. | Hsieh AR et al. | β | 2019 | β |
| Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. | Sharp BM et al. | β | 2019 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| Network analysis of the genomic basis of the placebo effect. | Wang RS et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Associations between smoking behavior-related alleles and the risk of melanoma. | Wu W et al. | β | 2016 | β |
| Associations of rare nicotinic cholinergic receptor gene variants to nicotine and alcohol dependence. | Zuo L et al. | β | 2016 | β |
| Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use. | Melroy-Greif WE et al. | β | 2016 | β |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | β | 2016 | β |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | β | 2015 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy. | Rocha Santos J et al. | β | 2015 | β |
| CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. | Chen LS et al. | β | 2015 | β |
| Is immunotherapy an opportunity for effective treatment of drug addiction? | Zalewska-Kaszubska J | β | 2015 | β |
| Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders. | YΔ±ldΔ±z M et al. | β | 2015 | β |
| Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. | Tyndale RF et al. | β | 2015 | β |
| Nicotine withdrawal. | McLaughlin I et al. | β | 2015 | β |
| Nicotinic receptor contributions to smoking: insights from human studies and animal models. | Brunzell DH et al. | β | 2015 | β |
| RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. | Webb A et al. | β | 2015 | β |
| The possible role of maternal bonding style and CHRNB2 gene polymorphisms in nicotine dependence and related depressive phenotype. | Csala I et al. | β | 2015 | β |
| The Role of Nicotine in Schizophrenia. | Featherstone RE et al. | β | 2015 | β |
| A glimpse into the future - Personalized medicine for smoking cessation. | Bierut LJ et al. | β | 2014 | β |
| Antidepressants for smoking cessation. | Hughes JR et al. | β | 2014 | β |
| Association of the CHRNA4 neuronal nicotinic receptor subunit gene with frequency of binge drinking in young adults. | Coon H et al. | β | 2014 | β |
| CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction. | Chen LS et al. | β | 2014 | β |
| Correcting systematic inflation in genetic association tests that consider interaction effects: application to a genome-wide association study of posttraumatic stress disorder. | Almli LM et al. | β | 2014 | β |
| Effect of neuronal nicotinic acetylcholine receptor genes (CHRN) on longitudinal cigarettes per day in adolescents and young adults. | Cannon DS et al. | β | 2014 | β |
| Finding genomic function for genetic associations in nicotine addiction research: the ENCODE project's role in future pharmacogenomic analysis. | Vandenbergh DJ et al. | β | 2014 | β |
| Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. | Chen LS et al. | β | 2014 | β |
| Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. | Leventhal AM et al. | β | 2014 | β |
| APOE Ι4, an Alzheimer's disease susceptibility allele, and smoking cessation. | Ashare RL et al. | β | 2013 | β |
| Biomarkers for smoking cessation. | Bough KJ et al. | β | 2013 | β |
| Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. | de Viron S et al. | β | 2013 | β |
| Genomics and personalized medicine: <i>CHRNA5-CHRNA3-CHRNB4</i> and smoking cessation treatment. | Chen LS et al. | β | 2013 | β |
| Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. | David SP et al. | β | 2013 | β |
| Integrative variable selection via Bayesian model uncertainty. | Quintana MA et al. | β | 2013 | β |
| Native American ancestry affects the risk for gene methylation in the lungs of Hispanic smokers from New Mexico. | Leng S et al. | β | 2013 | β |
| Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. | Bergen AW et al. | β | 2013 | β |
| Nominal association with CHRNA4 variants and nicotine dependence. | Kamens HM et al. | β | 2013 | β |
| The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. | Bergen AW et al. | β | 2013 | β |
| The Twin Research Registry at SRI International. | Krasnow RE et al. | β | 2013 | β |
| Translational research in nicotine dependence. | Turner JR et al. | β | 2013 | β |
| Alpha-5 and -3 nicotinic receptor gene variants predict nicotine dependence but not cessation: findings from the COMMIT cohort. | Bousman CA et al. | β | 2012 | β |
| Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation. | Spruell T et al. | β | 2012 | β |
| A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. | Verhagen M et al. | β | 2012 | β |
| Comparative dynamics of four smoking withdrawal symptom scales. | Javitz HS et al. | β | 2012 | β |
| Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. | Leventhal AM et al. | β | 2012 | β |
| DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. | Lee W et al. | β | 2012 | β |
| Gender-stratified gene and gene-treatment interactions in smoking cessation. | Lee W et al. | β | 2012 | β |
| Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. | Leng S et al. | β | 2012 | β |
| Impact of genetic notification on smoking cessation: systematic review and pooled-analysis. | de Viron S et al. | β | 2012 | β |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. | King DP et al. | β | 2012 | β |
| The CHRNA5-A3-B4 gene cluster in nicotine addiction. | Berrettini WH et al. | β | 2012 | β |
| Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. | Swan GE et al. | β | 2012 | β |
| A CHRNA5 allele related to nicotine addiction and schizophrenia. | Hong LE et al. | β | 2011 | β |
| Association of CHRNA4 polymorphisms with smoking behavior in two populations. | Han S et al. | β | 2011 | β |
| Association of the calcyon neuron-specific vesicular protein gene (CALY) with adolescent smoking initiation in China and California. | Li D et al. | β | 2011 | β |
| Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking: a meta-analysis. | Ware JJ et al. | β | 2011 | β |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | β | 2011 | β |
| CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences. | Hoft NR et al. | β | 2011 | β |
| Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics. | Perkins KA et al. | β | 2011 | β |
| Ethical concerns related to developing pharmacogenomic treatment strategies for addiction. | Shields AE | β | 2011 | β |
| Genetic variation in the glutathione synthesis pathway, air pollution, and children's lung function growth. | Breton CV et al. | β | 2011 | β |
| Genetic variations in nitric oxide synthase and arginase influence exhaled nitric oxide levels in children. | Salam MT et al. | β | 2011 | β |
| Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. | Sarginson JE et al. | β | 2011 | β |
| New Mexican Hispanic smokers have lower odds of chronic obstructive pulmonary disease and less decline in lung function than non-Hispanic whites. | Bruse S et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Relapse prevention for addictive behaviors. | Hendershot CS et al. | β | 2011 | β |
| The galanin receptor 1 gene associates with tobacco craving in smokers seeking cessation treatment. | Lori A et al. | β | 2011 | β |
| Association and interaction analysis of variants in CHRNA5/CHRNA3/CHRNB4 gene cluster with nicotine dependence in African and European Americans. | Li MD et al. | β | 2010 | β |
| Associations of ECP (eosinophil cationic protein)-gene polymorphisms to allergy, asthma, smoke habits and lung function in two Estonian and Swedish sub cohorts of the ECRHS II study. | JΓΆnsson UB et al. | β | 2010 | β |
| ChIP-chip analysis of neurexins and other candidate genes for addiction and neuropsychiatric disorders. | Pedrosa E et al. | β | 2010 | β |
| Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. | Wang J et al. | β | 2010 | β |
| Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. | Bierut LJ | β | 2010 | β |
| Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. | Ray R et al. | β | 2010 | β |
| Genes involved with folate uptake and distribution and their association with colorectal cancer risk. | Figueiredo JC et al. | β | 2010 | β |
| Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. | De Ruyck K et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | β | 2010 | β |
| Refining the tobacco dependence phenotype using the Wisconsin Inventory of Smoking Dependence Motives: II. Evidence from a laboratory self-administration assay. | Piasecki TM et al. | β | 2010 | β |
| Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the FagerstrΓΆm test for nicotine dependence. | Wessel J et al. | β | 2010 | β |
| Risk gene variants for nicotine dependence: a success story in neuropsychiatric genetics with possible applications to drug development. | Winterer G | β | 2010 | β |
| A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. | Freathy RM et al. | β | 2009 | β |
| A systems biology network model for genetic association studies of nicotine addiction and treatment. | Thomas PD et al. | β | 2009 | β |
| Cellular events in nicotine addiction. | Penton RE et al. | β | 2009 | β |
| Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. | Greenbaum L et al. | β | 2009 | β |
| Dopamine genes and nicotine dependence in treatment-seeking and community smokers. | Bergen AW et al. | β | 2009 | β |
| Functional variants in the catalase and myeloperoxidase genes, ambient air pollution, and respiratory-related school absences: an example of epistasis in gene-environment interactions. | Wenten M et al. | β | 2009 | β |
| New insights into the genetics of addiction. | Li MD et al. | β | 2009 | β |
| Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. | Hardin J et al. | β | 2009 | β |
| Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. | Perkins KA et al. | β | 2009 | β |
| Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials. | Rudnick ND et al. | β | 2009 | β |
| Transdisciplinary Tobacco Use Research Centers: research achievements and future implications. | Baker TB et al. | β | 2009 | β |
| Variation in the GST mu locus and tobacco smoke exposure as determinants of childhood lung function. | Breton CV et al. | β | 2009 | β |
| Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care. | Baker TB et al. | β | 2008 | β |
| Antidepressants for smoking cessation. | Hughes JR et al. | β | 2007 | β |